miR-195 inhibits tumor progression by targeting RPS6KB1 in human prostate cancer

Clinical Cancer Research

Volumn 21, Issue 21, 2015, Pages 4922-4934

  Cai, Chao ^a   Chen, Qing Biao ^b   Han, Zhao Dong ^a   Zhang, Yan Qiong ^c   He, Hui Chan ^a   Chen, Jia Hong ^a   Chen, Yan Ru ^a   Yang, Sheng Bang ^a   Wu, Yong Ding ^a   Zeng, Yan Ru ^a,b   Qin, Guo Qiang ^d   Liang, Yu Xiang ^a   Dai, Qi Shan ^a   Jiang, Fu Neng ^a   Wu, Shu Lin ^e   Zeng, Guo Hua ^a   Zhong, Wei De ^a,b   Wu, Chin Lee ^e  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^d Panyu District Central Hospital   (China)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE B; MICRORNA; MICRORNA 195; PROTEIN BAD; PROTEIN RPS6KB1; S6 KINASE; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; 3' UNTRANSLATED REGION; CADHERIN; MESSENGER RNA; MIRN195 MICRORNA, HUMAN; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOCHEMICAL RECURRENCE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; GAIN OF FUNCTION MUTATION; GENE SILENCING; GENE TARGETING; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RPS6KB1 GENE; TUMOR INVASION; TUMOR VASCULARIZATION; 3' UNTRANSLATED REGION; ANIMAL; BINDING SITE; CELL MOTION; CHEMISTRY; DISEASE COURSE; DISEASE MODEL; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATE TUMOR; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR VOLUME;

3' UNTRANSLATED REGIONS; ANIMALS; APOPTOSIS; BASE SEQUENCE; BCL-ASSOCIATED DEATH PROTEIN; BINDING SITES; CADHERINS; CELL LINE, TUMOR; CELL MOVEMENT; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICRORNAS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROSTATIC NEOPLASMS; PROTEOMICS; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA INTERFERENCE; RNA, MESSENGER; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84940682233     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0217     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA Cancer J Clin 2013;63:11-30
2. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003;169:517-23.
3. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-6.
4. D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen MH. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003;21:2163-72.
5. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
6. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
7. Ayub SG, Kaul D, Ayub T. Microdissecting the role of microRNAs in the pathogenesis of prostate cancer. Cancer Genet 2015. pii: S2210-7762(15)00031-9.
8. Schmittgen TD. Regulation of microRNA processing in development, differentiation and cancer. J Cell Mol Med 2008;12:1811-9.
9. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-61.
10. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res 2007;67:6130-5.
11. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009;50:113-21.
12. Bhattacharya A, Schmitz U, Wolkenhauer O, Schonherr M, Raatz Y, Kunz M. Regulation of cell cycle checkpoint kinase WEE1 by miR-195 in malignant melanoma. Oncogene 2013;32:3175-83.
13. Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang Y, et al. Analysis of MiR-195 and MiR-497 expression, regulation and role in breast cancer. Clin Cancer Res 2011;17:1722-30.
14. Ding J, Huang S, Wang Y, Tian Q, Zha R, Shi H, et al. Genome-wide screening reveals that miR-195 targets the TNF-α/NF-κB pathway by down-regulating IκB kinase alpha and TAB3 in hepatocellular carcinoma. Hepatology 2013;58:654-66.
15. Soon PS, Tacon LJ, Gill AJ, Bambach CP, Sywak MS, Campbell PR, et al. miR-195 and miR-483-5p identified as predictors of poor prognosis in adrenocortical cancer. Clin Cancer Res 2009;15:7684-92.
16. Jia LF, Wei SB, Gong K, Gan YH, Yu GY. Prognostic implications of micoRNA miR-195 expression in human tongue squamous cell carcinoma. PLoS ONE 2013;8:e56634.
17. Fu MG, Li S, Yu TT, Qian LJ, Cao RS, Zhu H, et al. Differential expression of miR-195 in esophageal squamous cell carcinoma and miR-195 expression inhibits tumor cell proliferation and invasion by targeting of Cdc42. FEBS Lett 2013;587:3471-9.
18. Maragkakis M, Alexiou P, Papadopoulos GL, Reczko M, Dalamagas T, Giannopoulos G, et al. Accurate microRNA target prediction correlates with protein repression levels. BMC Bioinformatics 2009;10:295.
19. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011;44:839-47.
20. Betel D, Koppal A, Agius P, Sander C, Leslie C. Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010;11:R90.
21. Lin ZY, Huang YQ, Zhang YQ, Han ZD, He HC, Ling XH, et al. MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1. Int J Cancer 2014;135:541-50.
22. Chen G, Liang YX, Zhu JG, Fu X, Chen YF, Mo RJ, et al. CC chemokine ligand 18 correlates with malignant progression of prostate cancer. Biomed Res Int 2014;2014:230183.
23. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
24. Havel LS, Kline ER, Salgueiro AM, Marcus AI. Vimentin regulates lung cancer cell adhesion through a VAV2-Rac1 pathway to control focal adhesion kinase activity. Oncogene 2015;34:1979-90.
25. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008;455:58-63.
26. Harada H, Andersen JS, Mann M, Terada N, Korsmeyer SJ. p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD. Proc Natl Acad Sci U S A 2001;98:9666-70.
27. Zhou HY, Wong AS. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology 2006;147:2557-66.
28. Pon YL, Zhou HY, Cheung AN, Ngan HY, Wong AS. p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res 2008;68:6524-32.
29. Bian CX, Shi Z, Meng Q, Jiang Y, Liu LZ, Jiang BH. P70S6K1 regulation of angiogenesis through VEGF and HIF-1alpha expression. Biochem Biophys Res Commun 2010;398:395-9.
30. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Müller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology 2011;77:1265.
31. He JF, Luo YM, Wan XH, Jiang D. Biogenesis of MiRNA-195 and its role in biogenesis, the cell cycle, and apoptosis. J Biochem Mol Toxicol 2011;25:404-8.
32. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.
33. Ou M, Zhang X, Dai Y, Gao J, Zhu M, Yang X, et al. Identification of potential microRNA-target pairs associated with osteopetrosis by deep sequencing, iTRAQ proteomics and bioinformatics. Eur J Hum Genet 2014;22:625-32.
34. Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, et al. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis 2014;5:e1437.
35. Edlind MP, Hsieh AC. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J Androl 2014;16:378-86
36. Khotskaya YB, Goverdhan A, Shen J, Ponz-Sarvise M, Chang SS, Hsu MC, et al. S6K1 promotes invasiveness of breast cancer cells in a model of metastasis of triple-negative breast cancer. Am J Transl Res 2014;6:361-76.
37. Fleckenstein DS, Dirks WG, Drexler HG, Quentmeier H. Tumor necrosis factor receptor-associated factor (TRAF) 4 is a new binding partner for the p70S6 serine/threonine kinase. Leuk Res 2003;27:687-94.
38. de Groot RP, Ballou LM, Sassone-Corsi P. Positive regulation of the cAMP-responsive activator CREM by the p70 S6 kinase: an alternative route to mitogen-induced gene expression. Cell 1994;79:81-91.
39. Ip CK, Cheung AN, Ngan HY, Wong AS. p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene 2011;30:2420-32.
40. Li PD, Zhang WJ, Zhang MY, Yuan LJ, Cha YL, Ying XF, et al. Overexpression of RPS6KB1 predicts worse prognosis in primary HCC patients. Med Oncol 2012;29:3070-6.
41. Kim EK, Kim JH, Kim HA, Seol H, Seong MK, Lee JY, et al. Phosphorylated S6 kinase-1: a breast cancer marker predicting resistance to neoadjuvant chemotherapy. Anticancer Res 2013;33:4073-9.
42. Ben-Hur V, Denichenko P, Siegfried Z, Maimon A, Krainer A, Davidson B, et al. S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1. Cell Rep 2013;3:103-15.